Literature DB >> 16012865

Signal transduction through substance P receptor in human glioblastoma cells: roles for Src and PKCdelta.

Keisuke Yamaguchi1, Mark D Richardson, Darrell D Bigner, Madan M Kwatra.   

Abstract

Substance P receptor (SPR), a G protein-coupled receptor (GPCR), is found in human glioblastomas, and has been implicated in their growth. Consistent with a role for SPR in cell growth, activation of SPR in U373 MG human glioblastoma cells leads to the phosphorylation of mitogen-activated protein kinases [extracellular signal-regulated kinase 1 and 2 (ERK1/2)] and stimulation of cell proliferation. The purpose of the present study was to elucidate the pathway through which these actions occur. Using either the epidermal growth factor receptor (EGFR) kinase inhibitor, AG 1478, or a small-interfering RNA (siRNA) directed against human EGFR, we found that transactivation of EGFR by SPR is only marginally involved in SP-dependent ERK1/2 phosphorylation. Src, however, is shown to be a major component of SPR signaling because the Src kinase inhibitor, PP2, and a kinase-dead Src mutant both inhibit SP-dependent ERK1/2 phosphorylation. We also report that SPR stimulates the phosphorylation of protein kinase Cdelta(PKCdelta), and that this stimulation is blocked by PP2. SP-dependent ERK1/2 phosphorylation is also blocked by rottlerin, a PKCdelta inhibitor, and the calcium scavenger, BAPTA/AM. Finally, rottlerin and PP2 were both found to inhibit the growth of several glioblastoma cell lines, underscoring the potential of these agents to block glioblastoma growth.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16012865     DOI: 10.1007/s00280-005-1030-3

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  18 in total

1.  Overexpression of membrane metalloendopeptidase inhibits substance P stimulation of cholangiocarcinoma growth.

Authors:  Fanyin Meng; Sharon DeMorrow; Julie Venter; Gabriel Frampton; Yuyan Han; Heather Francis; Holly Standeford; Shanika Avila; Kelly McDaniel; Matthew McMillin; Syeda Afroze; Micheleine Guerrier; Morgan Quezada; Debolina Ray; Lindsey Kennedy; Laura Hargrove; Shannon Glaser; Gianfranco Alpini
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-03-06       Impact factor: 4.052

2.  Association of the GNB3 825T-allele with better survival in patients with glioblastoma multiforme.

Authors:  Nicolai El Hindy; Michael Adamzik; Nicole Lambertz; Hagen S Bachmann; Karl Worm; Rupert Egensperger; Ulrich H Frey; Siamak Asgari; Ulrich Sure; Winfried Siffert; I Erol Sandalcioglu
Journal:  J Cancer Res Clin Oncol       Date:  2010-02-10       Impact factor: 4.553

3.  Substance P derivatives as versatile tools for specific delivery of various types of biomolecular cargo.

Authors:  Shahir S Rizk; Agnieszka Misiura; Marcin Paduch; Anthony A Kossiakoff
Journal:  Bioconjug Chem       Date:  2011-12-23       Impact factor: 4.774

Review 4.  The emerging role of substance P/neurokinin-1 receptor signaling pathways in growth and development of tumor cells.

Authors:  Hossein Javid; Fariba Mohammadi; Elnaz Zahiri; Seyed Isaac Hashemy
Journal:  J Physiol Biochem       Date:  2019-08-01       Impact factor: 4.158

5.  A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptor-mediated apoptosis in glioblastomas.

Authors:  Toshimasa Akazawa; Shawn G Kwatra; Laura E Goldsmith; Mark D Richardson; Elizabeth A Cox; John H Sampson; Madan M Kwatra
Journal:  J Neurochem       Date:  2009-03-11       Impact factor: 5.372

6.  Involvement of SRC family kinases in substance P-induced chemokine production in mouse pancreatic acinar cells and its significance in acute pancreatitis.

Authors:  Raina Devi Ramnath; Jia Sun; Madhav Bhatia
Journal:  J Pharmacol Exp Ther       Date:  2009-02-11       Impact factor: 4.030

7.  Why cerebellar glioblastoma is rare and how that indicates adjunctive use of the FDA-approved anti-emetic aprepitant might retard cerebral glioblastoma growth: a new hypothesis to an old question.

Authors:  Richard E Kast
Journal:  Clin Transl Oncol       Date:  2009-07       Impact factor: 3.405

8.  EGF regulates plasminogen activator inhibitor-1 (PAI-1) by a pathway involving c-Src, PKCdelta, and sphingosine kinase 1 in glioblastoma cells.

Authors:  Barbara S Paugh; Steven W Paugh; Lauren Bryan; Dmitri Kapitonov; Katarzyna M Wilczynska; Sunita M Gopalan; Hanna Rokita; Sheldon Milstien; Sarah Spiegel; Tomasz Kordula
Journal:  FASEB J       Date:  2007-09-12       Impact factor: 5.191

9.  Differences in the length of the carboxyl terminus mediate functional properties of neurokinin-1 receptor.

Authors:  Jian-Ping Lai; Saien Lai; Florin Tuluc; Morris F Tansky; Laurie E Kilpatrick; Susan E Leeman; Steven D Douglas
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-19       Impact factor: 11.205

10.  An engineered substance P variant for receptor-mediated delivery of synthetic antibodies into tumor cells.

Authors:  Shahir S Rizk; Anna Luchniak; Serdar Uysal; Crista M Brawley; Ronald S Rock; Anthony A Kossiakoff
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-22       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.